Life Sciences Tools and Services

Applied DNA Sciences

Applied DNA Sciences Announces Holding Over $17 Million Worth of BNB and Launches Digital Asset Treasury Strategy

Applied DNA Sciences Inc. Issues Private Placement to Invest in Binance Ecosystem Through BNB

Applied DNA Sciences released FY2025 9 Months Earnings on August 14 After-Market EST, actual revenue USD 1.501 M, actual EPS USD -397.3282

Applied DNA Sciences released FY2025 Q3 earnings on August 14 After-Market EST, actual revenue USD 304.39K (forecast USD 1.276M), actual EPS USD -33.9977 (forecast USD -37.4999)

Applied DNA to Release Q3 2025 Earnings Report

Applied DNA Sciences Inc Reports Widened Quarterly EPS Loss

Applied DNA Sciences released FY2025 Q2 earnings on May 15 After-Market EST, actual revenue USD 0 (forecast USD 1.185 M), actual EPS USD 0 (forecast USD -44.9999)

Applied DNA Sciences released FY2025 Semi-Annual earnings on May 15 After-Market EST, actual revenue USD 2.18 M, actual EPS USD -507.2482

Applied DNA Sciences Q2 2025 Therapeutic DNA Segment Revenue Up 44%

Applied DNA Sciences Inc Expected to Report Q1 2025 EPS Loss of $3.00

Applied DNA Sciences Inc Sees 27.5% Revenue Growth in Q1

Applied DNA Sciences Meets Nasdaq Minimum Bid Price Requirement, Stock Price Rises 20%

Applied DNA Sciences Repositions Genomic Testing Services

Applied DNA Sciences released FY2025 Q1 earnings on February 13 After-Market EST, actual revenue USD 1.197 M (forecast USD 1.175 M), actual EPS USD -417.5284 (forecast USD -247.4998)

Applied DNA Sciences Inc Reports Quarterly Financial Data with 34.3% Revenue Growth

Applied DNA Sciences Inc expects 16.4% revenue growth in 2024

Applied DNA Sciences to Release FY2025 Q1 Earnings on February 13 After-Market (EST), Forecast Revenue 1.175 M USD, EPS -0.33 USD

Applied DNA Sciences released FY2024 Q4 earnings on December 17 After-Market EST, actual revenue USD 813.11 K (forecast USD 899 K), actual EPS USD -240.0074 (forecast USD -254.9998)

Applied DNA Sciences released FY2024 earnings on December 17 After-Market EST, actual revenue USD 3.431 M (forecast USD 3.517 M), actual EPS USD 0 (forecast USD -3.27 K)

Applied DNA Sciences to Release FY2024 Q4 Earnings on December 17 After-Market EST, Forecast Revenue 899K USD, EPS -0.34 USD

The Gabelli Equity Trust Inc.

Cyclerion Therapeutics

PMGC

Axe Compute

Mega Fortune

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

System1

RYTHM

U Power

RenX Enterprises

ChromaDex

Agilent Tech

Waters

West Pharmaceutical

WuXi Biologics

Medpace

Repligen

Stevanato Group SpA

Thermo Fisher Scentific

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Applied DNA Sciences(APDN.US)

Applied DNA Sciences Stock Performance Chart